Loading…
Ernexa Therapeutics Inc. is projected to decline to $3.31 by 2027, a -4% move from its current price of $3.45. ERNA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $3.24 | $3.45 | $3.68 | +0.03% |
| Aug 6 | $3.15 | $3.45 | $3.78 | +0.07% |
| Aug 7 | $3.09 | $3.45 | $3.86 | +0.10% |
| Aug 8 | $3.04 | $3.45 | $3.93 | +0.14% |
| Aug 9 | $2.99 | $3.46 | $3.99 | +0.17% |
| Aug 10 | $2.95 | $3.46 | $4.05 | +0.21% |
| Aug 11 | $2.92 | $3.46 | $4.10 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.92 | $3.46 | $4.10 | +0.24% |
| Week 2 | $2.72 | $3.47 | $4.41 | +0.48% |
| Week 3 | $2.59 | $3.47 | $4.67 | +0.72% |
| Week 4 | $2.48 | $3.48 | $4.90 | +0.96% |
| Week 5 | $2.39 | $3.49 | $5.11 | +1.21% |
| Week 6 | $2.31 | $3.50 | $5.31 | +1.45% |
| Week 7 | $2.24 | $3.51 | $5.51 | +1.69% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ernexa Therapeutics Inc. is a preclinical-stage healthcare company focused on developing iMSC therapies for cancer and autoimmune disease. Its lead product ERNA-101 is an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer, and ERNA-201 is an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
The company has a license agreement with Factor Bioscience Limited. It was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics was founded in 2018 and is based in Cambridge, Massachusetts.
Ernexa Therapeutics Inc. trades under the symbol ERNA. The current price is $3.28 and the market capitalization is $3.83M, with a market rank of 5340.
The near-term outlook shows a flat-to-moderate path, with 2026 forecasted average price of $3.28 and ROI of 0, and a 30-day price range between $2.15 and $5.01. The longer-term forecast indicates gradual gains toward 2030–2050, including a 2030 average of $3.66 (ROI 11.5) and a 2040 average of $3.97 (ROI 21), culminating in a 2050 average of $8.98 (ROI 173.8).
Overall, the forecast depicts mixed early-year performance with neutral to bear sentiment in 2026–2029, followed by bullish momentum in 2040 and 2050 as the average price climbs toward higher levels and ROI expands.
A major floor 84.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.9% below — buyers have tended to step in here.
The nearest ceiling, 114.5% above — a clean break opens room to run.
A major ceiling 295.1% above — clearing it would confirm fresh momentum.
Key ERNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ERNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.54 | Sell | $3.58 | Sell |
| MA 10 | $4.00 | Sell | $4.07 | Sell |
| MA 20 | $5.11 | Sell | $4.84 | Sell |
| MA 50 | $6.82 | Sell | $6.15 | Sell |
| MA 100 | $6.58 | Sell | $9.04 | Sell |
| MA 200 | $17.11 | Sell | $26.90 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 29.10 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -107.03 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | -51.26 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.70 | Sell |
| Awesome (5,34) | -2.12 | Sell |
| Ultimate (7,14,28) | 16.42 | Buy |
| Momentum (10) | -3.14 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 3.21 | Buy |
| ADX (14) | 25.63 | Sell |
| ATR (14) | 0.36 | Info |
The 30-day technical picture is NEUTRAL, with RSI(14) at 30. This suggests the stock is near the lower end of its neutral range.
Prices are trading well below key moving averages, with SMA50 at $6.82 and SMA200 at $17.11, reinforcing a weaker near-term posture.
Near-term support sits at $3.28 and resistance at $7.40, while the 30-day price range runs from $2.15 to $5.01. These levels help frame the immediate risk and potential bounce points for ERNA.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.28 | $3.45 | $4.53 | 0% | Neutral | |
| $2.41 | $3.31 | $4.91 | -4% | Neutral | |
| $1.67 | $2.44 | $3.86 | -29% | Bearish | |
| $1.79 | $2.75 | $4.57 | -20% | Bearish | |
| $2.39 | $3.85 | $6.67 | +12% | Neutral | |
| $2.22 | $3.75 | $6.72 | +9% | Neutral | |
| $2.31 | $4.07 | $7.52 | +18% | Neutral | |
| $2.15 | $3.94 | $7.48 | +14% | Neutral | |
| $1.65 | $3.14 | $6.12 | -9% | Neutral | |
| $1.80 | $3.56 | $7.10 | +3% | Neutral | |
| $1.88 | $4.18 | $9.16 | +21% | Bullish | |
| $4.25 | $9.43 | $21.70 | +173% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.28 | $3.45 | $4.27 | +0.00% |
| September 2026 | $3.00 | $3.64 | $4.62 | +5.53% |
| October 2026 | $2.89 | $3.56 | $4.61 | -2.24% |
| November 2026 | $2.69 | $3.35 | $4.41 | -5.79% |
| December 2026 | $2.70 | $3.40 | $4.53 | +1.30% |
Click any year to see its month-by-month ERNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ERNA is projected to trade between $3.28 and $4.53, averaging $3.45 — a potential gain of 0% from today's $3.45. A consolidation phase looks the most probable path here.
Ernexa Therapeutics Inc.'s 2027 outlook centres on $3.31, within a $2.41 to $4.91 range. That is -4% versus the projected 2026 average. That marks a -4% change versus current levels. Price action looks broadly range-bound.
By 2028, ERNA could reach as high as $3.86, with a base case around $2.44 and support toward $1.67 — roughly -29% from $3.45. Expect choppier, lower action through this leg of the cycle.
Expect ERNA to range from $1.79 to $4.57 through 2029. The $2.75 average target implies a -20% move from current prices. That is up +13% on the projected 2028 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The ERNA price prediction for 2030 points to an average of $3.85 (low $2.39, high $6.67) — a potential gain of +12% on today's $3.45. A consolidation phase looks the most probable path here.
In 2031, ERNA is projected to trade between $2.22 and $6.72, averaging $3.75 — a potential gain of +9% from today's $3.45. That is -3% versus the projected 2030 average. Price action looks broadly range-bound.
Ernexa Therapeutics Inc.'s 2032 outlook centres on $4.07, within a $2.31 to $7.52 range. That is up +8% on the projected 2031 average. That marks a +18% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, ERNA could reach as high as $7.48, with a base case around $3.94 and support toward $2.15 — roughly +14% from $3.45. Price action looks broadly range-bound.
Expect ERNA to range from $1.65 to $6.12 through 2034. The $3.14 average target implies a -9% move from current prices. That is -20% versus the projected 2033 average. A consolidation phase looks the most probable path here.
The ERNA price prediction for 2035 points to an average of $3.56 (low $1.80, high $7.10) — a potential gain of +3% on today's $3.45. Price action looks broadly range-bound.
In 2040, ERNA is projected to trade between $1.88 and $9.16, averaging $4.18 — a potential gain of +21% from today's $3.45. That is up +17% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Ernexa Therapeutics Inc.'s 2050 outlook centres on $9.43, within a $4.25 to $21.70 range. That is up +126% on the projected 2040 average. That marks a +173% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ERNA today (≈ 289.855072 ERNA) could be worth
$2,734.34
+$1,734.34 (+173%) by 2050 · US Dollar
Based on the average projected ERNA price of $9.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ERNAwould be worth at today's price.
$1,000 invested in ERNA on Jul 31, 2025 (≈ 23.121387 ERNA) would be worth
$79.77
-$920.23 (-92.0%) today · 0.08× · US Dollar
Based on a ERNA entry price of $43.25 vs. today's $3.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.93 | $877.86 | -12.2% |
| 1 month ago | $6.7 | $514.93 | -48.5% |
| 3 months ago | $3.75 | $920 | -8.0% |
| 6 months ago | $31 | $111.29 | -88.9% |
| 1 year ago | $43.25 | $79.77 | -92.0% |
| All time (5.0y) ago | $85,875 | $0.04 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ERNA forecast.
Our base-case forecast reaches $6.90 around 2050.
Implied market cap at $6.90: $8.05M
The year-by-year forecast shows a cautious start and a more meaningful lift later on. For 2026, the average price is $3.28 with a min of $3.28 and a max of $4.32, and ROI of 0; sentiment is NEUTRAL. In 2027 the min is $2.29, avg is $3.14, max is $4.66, with ROI -4.3, sentiment NEUTRAL.
The outlook remains BEARISH for 2028 (min $1.59, avg $2.32, max $3.67, ROI -29.3) and 2029 (min $1.71, avg $2.62, max $4.36, ROI -20).
From 2030 onward, the forecast shifts higher: 2030 min $2.27, avg $3.66, max $6.33, ROI 11.5; 2031 min $2.11, avg $3.56, max $6.39, ROI 8.6; 2032 min $2.20, avg $3.87, max $7.16, ROI 18.1; 2033 min $2.04, avg $3.74, max $7.11, ROI 14; 2034 min $1.56, avg $2.98, max $5.81, ROI -9.2; 2035 min $1.71, avg $3.39, max $6.77, ROI 3.4.
The 2040 forecast is bullish, with min $1.79, avg $3.97, max $8.70 and ROI 21, and sentiment BULLISH. By 2050, the min is $4.04, avg $8.98, max $20.65, ROI 173.8, with sentiment BULLISH. These outputs imply a path from near-term flat performance toward substantial upside in the long run, albeit with notable risk in the earlier years.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.66 with a min of $2.27 and a max of $6.33, and ROI of 11.5. The sentiment is NEUTRAL.
Near term (2026–2029) shows mixed signals with ROI ranging from 0 to negative values (-4.3, -29.3, -20) and neutral to bearish sentiment. Long term (2040–2050) shows bullish momentum with ROI of 21 in 2040 and 173.8 in 2050, but these are estimates and not guaranteed.
The 2050 forecast lists a max of $20.65 with an average of $8.98, indicating a possible approach toward the upper end but not a guaranteed attainment.
Current price is $3.28 and market capitalization is $3.83M.
In 2040, the forecast shows an average price of $3.97, with a min of $1.79 and a max of $8.70, and ROI of 21. The sentiment is BULLISH.
Ernexa Therapeutics Inc. Community Discussion
0Share your Ernexa Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.